Please login to the form below

Not currently logged in
Email:
Password:

Vivid

This page shows the latest Vivid news and features for those working in and with pharma, biotech and healthcare.

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

Today’s BE SURE findings are consistent with the positive results we recently announced for both BE VIVID and BE READY,” said Iris Loew-Friedrich, head of drug development and chief ... This includes a recent phase 3 BE VIVID study comparing the drug

Latest news

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 20 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...